In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ciclopirox, Batrafen, Loprox, Mycoster, Stieprox, HOE 296b, Penlac Drug Master File in Korea (Ciclopirox, Batrafen, Loprox, Mycoster, Stieprox, HOE 296b, Penlac KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ciclopirox, Batrafen, Loprox, Mycoster, Stieprox, HOE 296b, Penlac. The MFDS reviews the Ciclopirox, Batrafen, Loprox, Mycoster, Stieprox, HOE 296b, Penlac KDMF as part of the drug registration process and uses the information provided in the Ciclopirox, Batrafen, Loprox, Mycoster, Stieprox, HOE 296b, Penlac KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ciclopirox, Batrafen, Loprox, Mycoster, Stieprox, HOE 296b, Penlac KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ciclopirox, Batrafen, Loprox, Mycoster, Stieprox, HOE 296b, Penlac API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ciclopirox, Batrafen, Loprox, Mycoster, Stieprox, HOE 296b, Penlac suppliers with KDMF on PharmaCompass.